. 2022 Aug 15;12(8):3512–3531.

Table 3.

Studies on the omission of axillary lymph node dissection

Study	Period	Type	Inclusion	n	Treatment of axillary	Follow-up	Results
NSABP B-04 [75]	1971-1974	prospective	primary operable breast cancer	1765	1079 cN₀ (1/3 ALND; 1/3 RT; 1/3 no surgery)	25 years	NS in RFS, DFS, or OS
NSABP B-04 [75]	1971-1974	prospective	primary operable breast cancer	1765	586 cN+ (1/2 RT; 1/2 ALND)	25 years	NS in RFS, DFS, or OS
AMAROS [93]	2001-2010	prospective	T1-2, cN₀	4806	2402 ALND	6.1 years	ALND vs RT:
					2404 RT		5-year axillary recurrence
					1425 cN+		0.43% vs 1.19%
					744 ALND; 681 RT		DFS: 86.9% vs 82.7%
							OS: 81.4% and 84.6%
ACOSOG Z0011 [94]	1999-2004	prospective	T1-2, cN₀;	891	446 SLND alone	9.3 years	SLND vs ALND
			N1-2		445 ALND		OS: 86.3% vs 83.6%
							DFS: 80.2% vs 78.2%
							NS in LRR
Alliance A011202	2013-	prospective	T1-3, N1, M0	1660	ALND vs RT.	-	No results
NRG9353	2003-	prospective	T1-3, N1, M0	1636	ALND vs RT	-	No results

Abbreviations: OS, overall survival; DFS, disease-free survival; RFS, relapse-free survival; LRR, locoregional recurrence rate; NAC, neoadjuvant chemotherapy; pCR, pathological complete response; cCR, clinical complete response; ALND, axillary lymph node dissection; SLND, sentinel lymph node biopsy; TAD, targeted axillary dissection; RT, radiotherapy treatment; NS, no significant.